Sharekhan

Gufic BioSciences Ltd

Fri 6/03/2026,15:44:54 NSE: GUFICBIO

₹ 279.15 1.55 (0.56%)
BUY NOW Buy Gufic BioSciences Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Gufic BioSciences Ltd

Fri 6/03/2026,16:1:0

Gufic BioSciences Ltd

Fri 6/03/2026,15:44:54 | NSE : GUFICBIO

₹ 279.151.55 (0.56%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 274.95

Previous Close

₹ 277.60

Volume

42780

Mkt Cap ( Rs. Cr)

₹2799.39

High

₹ 281.00

Low

₹ 272.50

52 Week High

₹ 407.85

52 Week Low

₹ 270.60

Book Value Per Share

₹ 64.17

Dividend Yield

0.03

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Gufic BioSciences Ltd

Your Vote -

Buy

84.00%

Hold

12.00%

Sell

4.00%

84.00%

25 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

279.15

71

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

71

Option Chain

Analyzes market sentiment, predicts Gufic BioSciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Gufic BioSciences - Copy of Newspaper Publication

    24 Feb 2026, 6:50PM Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Publication

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    20 Feb 2026, 5:14PM Written Transcript of Earnings Conference Call held on February 16, 2026 at 04:30 PM is attached herewith.

  • Gufic BioSciences - Analysts/Institutional Investor Meet/Con. Call Updates

    20 Feb 2026, 5:02PM Gufic Biosciences Limited has informed the Exchange about Transcript

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    16 Feb 2026, 7:25PM Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Audio Rec

  • Gufic BioSciences - Analysts/Institutional Investor Meet/Con. Call Updates

    16 Feb 2026, 7:02PM Gufic Biosciences Limited has informed the Exchange about Link of Recording

  • Gufic BioSciences - Copy of Newspaper Publication

    14 Feb 2026, 2:18PM Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Publication

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Investor Presentation

    13 Feb 2026, 10:39PM Investor Presentation is attached herewith

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Acquisition

    13 Feb 2026, 10:34PM Intimation of further investment in Selvax Pty Ltd. is attached herewith

  • Gufic BioSciences - Acquisition

    13 Feb 2026, 10:30PM Gufic Biosciences Limited has informed the Exchange about Acquisition

  • Gufic BioSciences - Investor Presentation

    13 Feb 2026, 10:25PM Gufic Biosciences Limited has informed the Exchange about Investor Presentation

  • Gufic BioSciences Q3 net profit down 19.46% at Rs 15.56 cr

    13 Feb 2026, 10:20PM The company reported standalone net profit of Rs 15.56 crore for the quarter ended December 31, 2025 as compared to Rs 19.32 crore in the same period

  • Gufic BioSciences - Board Meeting Outcome for For Meeting Held On Friday, February 13, 2026

    13 Feb 2026, 10:08PM Outcome of the Board of Directors Meeting held on Friday, February 13, 2026 is attached herewith

  • Gufic BioSciences - Outcome of Board Meeting

    13 Feb 2026, 10:07PM Gufic Biosciences Limited has informed the Exchange regarding Outcome of Board Meeting held on February 13, 2026.

  • Gufic BioSciences - Outcome of Board Meeting

    13 Feb 2026, 10:00PM Gufic Biosciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.

  • Gufic BioSciences - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Feb 2026, 7:06PM Gufic Biosciences Limited has informed the Exchange about Schedule of meet

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Feb 2026, 7:01PM Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requireme

  • Gufic BioSciences - Board Meeting Intimation for Consideration And Approval Of, Inter Alia, Unaudited Financial Results (Stan

    9 Feb 2026, 6:47PM Gufic Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider an

  • Gufic BioSciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 Feb 2026, 6:45PM Intimation of Schedule of Analyst/ Institutional Investor meeting is attached herewith.

  • Gufic BioSciences - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Feb 2026, 6:24PM Gufic Biosciences Limited has informed the Exchange about Schedule of meet

  • Gufic BioSciences - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations,

    20 Jan 2026, 7:58PM Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith

  • Gufic BioSciences - General Updates

    20 Jan 2026, 7:45PM Gufic Biosciences Limited has informed the Exchange about Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)

  • Gufic BioSciences has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025

    16 Jan 2026, 2:20PM As of December 2025, 72.50% is owned by Indian Promoters and 27.50% by Public. <p align=justify> Top five Promoters holding highest number of shares o

  • Gufic BioSciences - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    6 Jan 2026, 7:12PM Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025 is attached herew

  • Gufic BioSciences - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    6 Jan 2026, 7:12PM Gufic Biosciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Gufic BioSciences - Trading Window

    30 Dec 2025, 4:56PM Gufic Biosciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations

  • Gufic BioSciences - General Updates

    27 Dec 2025, 10:17PM Gufic Biosciences Limited has informed the Exchange about Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)

  • Gufic BioSciences - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations,

    27 Dec 2025, 10:00PM Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith.

  • Gufic BioSciences Lt - General Updates

    10 Dec 2025, 5:54PM Gufic Biosciences Limited has informed the Exchange about Environmental, Social and Governance (ESG) Rating

  • Gufic BioSciences Lt - Intimation Of Environmental, Social And Governance ('ESG') Rating

    10 Dec 2025, 5:45PM Intimation of ESG Rating is attached herewith

  • Gufic receives NMPA China nod for Prilocaine API

    19 Jun 2023 , 11:58AM Gufic Biosciences gets NMPA approval for Prilocaine API

  • Gufic BioSciences

    7 Jun 2022 , 10:08AM Gufic Biosciences: Has launched a new drug delivery system - Dual Chamber Bags at affordable price first time in the India markets. The product launch is basis the collaboration with its European partner. The dual chamber bags come with a peelable aluminium foil allowing the storage of unstable drugs which needs reconstitution just before the administration to the patient. With the launch of this product Gufic aims to capture a major share of Rs 3000 cr lyophilized antibacterial market in India and hence is Positive, though we do not have a coverage on the stock.

  • Gufic Bio gets two patent certificates; stk gains

    6 Jun 2017 , 12:58PM Gufic Biosciences rises over 7% to Rs73.75, after receiving two patent certificates from Intellectual Property India
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Gufic BioSciences Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 911.7374 849.595 659.2153 330.3601 225.1873
Liabilities 911.7374 849.595 659.2153 330.3601 225.1873
Equity 10.0278 10.0278 9.6945 9.6945 9.6945
Gross Profit 136.3959 145.8714 134.6513 145.7147 83.9195
Net Profit 69.9328 86.1356 79.7048 95.8401 44.2316
Cash From Operating Activities 122.7777 -7.4571 -26.5872 104.4442 89.0648
NPM(%) 8.53 10.67 11.54 12.3 9.06
Revenue 819.806 806.6657 690.6208 779.1556 487.6987
Expenses 683.4101 660.7943 555.9695 633.4409 403.7792
ROE(%) 10.86 13.38 12.38 14.89 6.87

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
22 Sep 2025 0.1 10 0.04 391
18 Sep 2024 0.1 10 0.04 321.05
24 Aug 2022 0.1 10 0.04 243.9
09 Sep 2021 0.1 10 0.04 190.7
03 Nov 2020 0.05 5 0.04 102.1
20 Sep 2019 0.05 5 0.04 59.7
0.05 5 0.04 145.55
28 Aug 2017 0.05 5 0.04 66.25
19 Sep 2016 0.05 5 0.04 41.05
22 Sep 2015 0.05 5 0.04 14.05
18 Sep 2014 0.05 5 0.04 20.9
02 Sep 2013 0.05 5 0.04 5.55
16 Aug 2012 0.05 5 0.04 7.75
16 Sep 2011 0.05 5 0.04 6.05
20 Sep 2010 0.05 5 0.04 6.35
17 Sep 2009 0.05 5 0.04 6.35
11 Dec 2008 0.05 5 0.04 4.45
19 Mar 2008 0.05 5 0.04 9.45
20 Sep 2006 0.16 16 0.04 11.7
22 Sep 2005 0.22 22 0.04 29.75

Peers

Other companies within the same industry or sector that are comparable to Gufic BioSciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 680.05 -0.22 40.38 158.55 301.39 0.74
Lotus Eye Hospital and Institute Ltd 111.11 0.10 358.42 577.72 3.55 0.00
Vaishali Pharma Ltd 6.74 0.75 0.00 3624.24 3.13 0.00
Astec Lifesciences Ltd 627.60 -0.83 0.00 544.80 -604.75 0.00

Company Info

Central Finance Ltd. is a Bombay based company engaged in leasing, bill discounting, loan syndication, merchant banking/advisory services, investments, debt operations, portfolio management scheme, underwriting etc. Central Finance Securities Ltd. is the subsidiary of the company. The company has 100% stake in the subsidiary. 2000 - The Company name of changed to Gufic Biosciences Ltd. 2003 -Forays into vegetables market under the brand 'Gufic seeds'. 2004 -Gufic Biosciences eyes JV in biotech biz 2005 -Gufic Biosciences - Launch of new products 2007 -Gufic Biosciences Ltd has appointed Dr. M C Dhapalapur as Director of the Company on the Board of Directors of the Company with effect from August 01, 2007. 2008 - The Company has set up manufacturing facility for manufacture of Oncology Products. 2012 - The Board of Directors of the Company, inter alia, has recommended dividend @ 5% per share (i.e. Re. 0.05 per share). 2013 -Gufic Biosciences Ltd has irecommended dividend @ 5% per share (i.e. Re. 0.05 per share). 2014 - Ms. Hemal Deasi, Non- Independent Director has been appointed as an Additional Director. -Gufic Biosciences Ltd has recommended a dividend of Re. 0.05 per share on equity share of Rs. 1/- each. 2020-The company received approval for the Scheme of Amalgamation of Gufic Lifesciences Private Limited (the 'Transferor Company') with Gufic Biosciences Limited  (the 'Transferee Company' or 'Company').2021-The Company has approved the proposal for increasing Capital Expenditure to the tune of Rs. 200 Crores out of which around Rs. 180 crores is proposed to be utilized for setting up of the Company's new manufacturing unit and balance Rs. 20 Crores for setting up the Research & Development facility, both in Indore, Madhya Pradesh.2022-The Company approved the signing of Equity Subscription Agreement with M/s. Selvax Pty Limited ('Selvax'), a biotechnology company based in Perth, Western Australia, for subscription of 1,307,000  fully paid ordinary equity shares in Selvax aggregating to 2.67% of its total paid up share capital for a subscription fee of around USD 0.07651 per equity share aggregating to USD 100,000/- and the Company have also entered into a research and collaboration agreement with Selvax to accelerate the commercialization of Selvax's cancer immunotherapy treatment.

Central Finance Ltd. is a Bombay based company engaged in leasing, bill discounting, loan syndication, merchant banking/advisory services, investments, debt operations, portfolio management scheme, underwriting etc. Central Finance Securities Ltd. is the subsidiary of the company. The company has 100% stake in the subsidiary. 2000 - The Company name of changed to Gufic Biosciences Ltd. 2003 -Forays into vegetables market under the brand 'Gufic seeds'. 2004 -Gufic Biosciences eyes JV in biotech biz 2005 -Gufic Biosciences - Launch of new products 2007 -Gufic Biosciences Ltd has appointed Dr. M C Dhapalapur as Director of the Company on the Board of Directors of the Company with effect from August 01, 2007. 2008 - The Company has set up manufacturing facility for manufacture of Oncology Products. 2012 - The Board of Directors of the Company, inter alia, has recommended dividend @ 5% per share (i.e. Re. 0.05 per share). 2013 -Gufic Biosciences Ltd has irecommended dividend @ 5% per share (i.e. Re. 0.05 per share). 2014 - Ms. Hemal Deasi, Non- Independent Director has been appointed as an Additional Director. -Gufic Biosciences Ltd has recommended a dividend of Re. 0.05 per share on equity share of Rs. 1/- each. 2020-The company received approval for the Scheme of Amalgamation of Gufic Lifesciences Private Limited (the 'Transferor Company') with Gufic Biosciences Limited  (the 'Transferee Company' or 'Company').2021-The Company has approved the proposal for increasing Capital Expenditure to the tune of Rs. 200 Crores out of which around Rs. 180 crores is proposed to be utilized for setting up of the Company's new manufacturing unit and balance Rs. 20 Crores for setting up the Research & Development facility, both in Indore, Madhya Pradesh.2022-The Company approved the signing of Equity Subscription Agreement with M/s. Selvax Pty Limited ('Selvax'), a biotechnology company based in Perth, Western Australia, for subscription of 1,307,000  fully paid ordinary equity shares in Selvax aggregating to 2.67% of its total paid up share capital for a subscription fee of around USD 0.07651 per equity share aggregating to USD 100,000/- and the Company have also entered into a research and collaboration agreement with Selvax to accelerate the commercialization of Selvax's cancer immunotherapy treatment.

Read More

Parent Organisation

Gufic BioSciences Ltd.

Founded

23/07/1984

Managing Director

Mr.Jayesh P Choksi

NSE Symbol

GUFICBIOEQ

FAQ

The current price of Gufic BioSciences Ltd is ₹ 279.15.

The 52-week high for Gufic BioSciences Ltd is ₹ 281.00 and the 52-week low is ₹ 272.50.

The market capitalization of Gufic BioSciences Ltd is currently ₹ 2799.39. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Gufic BioSciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Gufic BioSciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Gufic BioSciences Ltd shares.

The CEO of Gufic BioSciences Ltd is Mr.Jayesh P Choksi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT